Scholar Rock Holding (SRRK) news

Scholar Rock Holding Corporation - Anticipates CHMP opinion on ApteGromab mAb in H1 2027

Trading resumed: NSTR (TXSE)

Trading resumed on the Texas Stock Exchange (TXSE) with the resumption of activity for the NSTR symbol, following the exchange’s phased launch earlier in the year. The TXSE, which commenced production trading on July 6 with test securities and transitioned to live trading on July 10, continues to…

Scholar Rock added to Wedbush best ideas list

Scholar Rock, a biotechnology company focused on developing therapeutics for fibrotic diseases, has been added to Wedbush Securities' best ideas list for the current quarter. The inclusion reflects the firm's positive outlook on the company's pipeline and strategic positioning within the biotech…

Scholar Rock Holding Corporation: Truist Securities raises target price to $77 from $76

Truist Securities has raised its price target for Scholar Rock Holding Corporation (SRRK) to $77 from $76, maintaining a "Buy" rating for the stock. The adjustment reflects the firm’s continued confidence in the company’s growth prospects and its therapeutic pipeline, particularly in the area of…

Scholar Rock Holding Corporation: Wedbush raises target price to $70 from $64

Wedbush analyst firm has raised its price target for Scholar Rock Holding Corporation (SRRK) to $70 from $64, reflecting positive outlook on development pipeline . This adjustment aligns with the broader consensus among 13 analysts, who maintain a "Buy" rating for SRRK, with 54% recommending…